Researchers uncover immune system barrier to cancer treatment

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.

China NMPA approves KeChow’s tunlametinib for melanoma

Share this article In a Phase II trial in melanoma patients, tunlametinib demonstrated an overall response rate of 35.8%. Credit: Africa Studio / Shutterstock.com. The

March 19, 2024

Can falsified or substandard antimicrobials increase antimicrobial resistance?

The association between substandard or falsified (SF) antibiotics and antimicrobial resistance (AMR).

October 5, 2023

Eye Drop Company in FDA’s Sights Once Again

The FDA has sent another letter — this time a warning letter — to a company that it previously flagged for marketing amniotic fluid eye

September 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.